Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)

Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)

Abstract Introduction SEL-212 is a developmental treatment for uncontrolled gout characterized by serum uric acid (sUA) levels ≥ 6 mg/dl despite treatment. It comprises a novel PEGylated uricase (SEL-037; also called pegadricase) co-administered with tolerogenic nanoparticles containing sirolimus (r...

Full description

Bibliographic Details
Main Authors: Alan Kivitz, Wesley DeHaan, Rehan Azeem, Justin Park, Sheri Rhodes, Jamie Inshaw, Sheldon S. Leung, Savvas Nicolaou, Lloyd Johnston, Takashi K. Kishimoto, Peter G. Traber, Earl Sands, Hyon Choi
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-04-01
Series:Rheumatology and Therapy
Subjects:
Gout
Hyperuricemia
ImmTOR®
Polyethylene glycols
SEL-212
Uric acid
Online Access:https://doi.org/10.1007/s40744-023-00546-0

Internet

https://doi.org/10.1007/s40744-023-00546-0

Similar Items